Liver cancer is one of the world’s most prevalent malignancies, and is also the third leading cause of cancer death in China. Hepatitis and cirrhosis background is a major feature of liver cancer patients in China, which makes specific requirements that suits the national conditions in many aspects of prevention and control like screening diagnosis, treatment options, and prognosis follow-up. The Specifications for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition), which is based on China’s practice, proposes liver cancer staging in line with China’s national conditions and forms a multi-disciplinary joint diagnosis and treatment model based on surgical treatment. Liver transplantation is included in liver cancer as one of the surgical treatments option. It also emphasizes the support of evidence-based medicine. The Specifications for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition) may have laid a solid foundation for future diagnosis and treatment of liver cancer in China.
Objective To explore the feasibility and safety of liver transplantation (LT) in treatment of upper gastrointestinal hemorrhage in patients with portal hypertension, and to compare the therapeutic effects with conventional operation (CO). Methods The clinical data of 303 patients with bleeding portal hypertension from Feb. 2009 to Feb. 2012 in the department of hepatobiliary and pancreatic surgery of First Affiliated Hospital of Zhejiang University were retrospectively analyzed. One hundred and one patients received LT procedure (LT group), whereas the other 202 patients received CO procedure (CO group). Postoperative follow-up period was 8-44 months (average 26 months). Results Liver function before operation in CO group was significantly better than that in LT group(P<0.01). The mortality of CO group and LT group were 7.4%(14/189) and 3.0%(3/101, P=1.00), respectively. The rebleeding rate of patients underwent LT was 2.0%(2/101), significantly lower than that of CO group 〔9.5%(18/189), P<0.05〕. The vanish rate of esophagogastric varice in patients underwent LT was 86.1%(87/101), significantly lower than that of CO group 〔54.5%(86/189), P<0.01〕. Conclusions LT treatment for bleeding portal hypertension is feasible and safe. Patients with good liver function despite hemorrhage history may be managed satisfactorily with conventional surgery. LT is the only curative treatment for patients with portal hypertension in end-stage liver disease.